• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>African Journal of Biotechnology >Urinary tract infections caused by extended spectrum -lactamase (ESBL) producing Escherichia coli and Klebsiella pneumoniae
【24h】

Urinary tract infections caused by extended spectrum -lactamase (ESBL) producing Escherichia coli and Klebsiella pneumoniae

机译：产生大范围内酰胺酶（ESBL）的大肠杆菌和肺炎克雷伯菌引起的尿路感染

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Emerging antibiotic resistance due to?extended spectrum?β-lactamase (ESBL) production limited the use of?β-lactam antibiotics against?Escherichia coli?andKlebsiella pneumoniae.?This observational study was conducted at the Microbiologydepartment of the Children’s Hospital, Lahore Pakistan, from June, 2009 to November, 2010 to determine the frequency and antimicrobial resistance of ESBL producing?E. coli?and?K. pneumoniae. A total?of?13638 urine samples were processed for culture and antimicrobial sensitivity testing.?E. coli?and?K. pneumoniaewere identified using API 20E. A?double disk synergy test (DDST) was performed to determine ESBL production.?ESBL production was detected in?312 (57.4%)?E. coliand 386 (71.7%)?K. pneumoniae. A multidrug resistance pattern was seen in ESBL producing?E. coli?and?Klebsiella pneumoniae.?ESBL producing?E. coli?showed maximum resistance to cefotaxime (100%), ceftazidime (99.4%) and cefuroxime (93.3%) while minimum resistance was seen with meropenem (1.3%), piperacillin/tazobactam (10.3%) and nitrofurantoin (27.6%). ESBL producing?K. pneumoniae?showed maximum resistance to ceftazidime (100%), cefotaxime (98.7%) and cefuroxime (98.1%) while minimum resistance was seen withmeropenem (3.6%), piperacillin/tazobactam (17.6%), and nitrofurantoin (28.5%). In ESBL producing bacteria, high prevalence of antibacterial resistance of non-β-lactam antibiotics is a serious matter of concern.?Monitoring?of ESBL production and antimicrobial susceptibility testing are necessary to avoid treatment?failure in patients with urinary tract infection (UTI).
机译：由于“β-内酰胺酶谱”的扩展生产而出现的新的抗生素耐药性限制了针对“大肠杆菌”和“肺炎克雷伯菌”的“β-内酰胺”抗生素的使用。这项观察性研究是在巴基斯坦拉合尔儿童医院的微生物科进行的，从2009年6月至2010年11月，确定产生ESBL？E的频率和耐药性。大肠杆菌和？肺炎共处理了13638份尿液样本，以进行培养和抗菌素敏感性测试。大肠杆菌和？使用API​​ 20E鉴定肺炎。进行双盘协同试验（DDST）以确定ESBL的产生。在〜312（57.4％）·E中检测到ESBL的产生。大肠杆菌386（71.7％）？肺炎在ESBL产生ΔE中发现了多药耐药性模式。大肠杆菌和肺炎克雷伯菌。大肠杆菌表现出对头孢噻肟（100％），头孢他啶（99.4％）和头孢呋辛（93.3％）的最大耐药性，而美罗培南（1.3％），哌拉西林/他唑巴坦（10.3％）和硝基呋喃妥因（27.6％）的耐药性最小。 ESBL生产？肺炎杆菌显示出对头孢他啶（100％），头孢噻肟（98.7％）和头孢呋辛（98.1％）的最大耐药性，而美罗培南（3.6％），哌拉西林/他唑巴坦（17.6％）和硝基呋喃妥因（28.5％）的耐药性最低。在产生ESBL的细菌中，非β-内酰胺类抗生素的高耐药性流行是一个严重的问题。为避免治疗，必须监测ESBL的产生和进行药敏试验以避免尿路感染（UTI）患者失败。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号